Zhaoke Ophthalmology's Abbreviated NDA for Myopia Drug Accepted by Chinese Regulator

Like
Comment
Favorite

Zhaoke Ophthalmology's Abbreviated NDA for Myopia Drug Accepted by Chinese Regulator

MT Newswires Live01-03

Zhaoke Ophthalmology's (HKG:6622) abbreviated new drug application (ANDA) for NVK002 (low-dose atropine 0.01%) has been accepted by China's National Medical Products Administration, a Thursday bourse filing said.

The drug is indicated for the treatment of myopia progression in children, according to the ophthalmic pharmaceutical company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

22:28
Trump Signs Order Imposing Sanctions on Countries Importing Venezuelan Oil -White House
22:25
Mastermyne Group - Contract Encompasses Approximately 200 Roles at Appin Mine, Others
22:25
Mastermyne Group - Executed Contract for Contract Mining Services With Gear M Illawarra Met Coal
22:20
Fortis Inc - Net Proceeds to Reduce Borrowings and for General Corporate Purposes
22:20
Fortis Inc - Prices $600 Million Offering of 4.090% Senior Unsecured Notes Due 2032

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2500198695?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-03 18:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500198695","market":"hk","top_or_hot":-1,"title":"Zhaoke Ophthalmology's Abbreviated NDA for Myopia Drug Accepted by Chinese Regulator","media":"MT Newswires Live","content":"<html><body><p> Zhaoke Ophthalmology's (HKG:6622) abbreviated new drug application (ANDA) for NVK002 (low-dose atropine 0.01%) has been accepted by China's National Medical Products Administration, a Thursday bourse filing said.</p><p>The drug is indicated for the treatment of myopia progression in children, according to the ophthalmic pharmaceutical company.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology's Abbreviated NDA for Myopia Drug Accepted by Chinese Regulator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology's Abbreviated NDA for Myopia Drug Accepted by Chinese Regulator\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-03 18:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Zhaoke Ophthalmology's (HKG:6622) abbreviated new drug application (ANDA) for NVK002 (low-dose atropine 0.01%) has been accepted by China's National Medical Products Administration, a Thursday bourse filing said.</p><p>The drug is indicated for the treatment of myopia progression in children, according to the ophthalmic pharmaceutical company.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2500198695","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500198695","pubTimestamp":1735898541,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zhaoke Ophthalmology's  abbreviated new drug application  for NVK002  has been accepted by China's National Medical Products Administration, a Thursday bourse filing said.The drug is indicated for the treatment of myopia progression in children, according to the ophthalmic pharmaceutical company.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"兆科眼科近视药物简略NDA获中国监管机构受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":0.9},"content_text":"Zhaoke Ophthalmology's (HKG:6622) abbreviated new drug application (ANDA) for NVK002 (low-dose atropine 0.01%) has been accepted by China's National Medical Products Administration, a Thursday bourse filing said.The drug is indicated for the treatment of myopia progression in children, according to the ophthalmic pharmaceutical company.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}